J. Barben (St. Gallen, Switzerland), B. Karadag (Istanbul, Turkey)
Late Breaking Abstract - Association of lung clearance index with survival in patients with cystic fibrosis
J. Kurz (Bern, Switzerland), K. Ramsey (Bern, Switzerland), R. Kraemer (Bern, Switzerland), B. Spycher (Bern, Switzerland), R. Fischer Biner (Bern, Switzerland), P. Latzin (Bern, Switzerland), F. Singer (Bern, Switzerland)
|    |
How can gene-editing of human pluripotent stem cells help cystic fibrosis?
S. Cuevas Ocana (Newcastle upon Tyne, United Kingdom), A. Wong (Toronto, Canada), M. Aushev (Newcastle upon Tyne, United Kingdom), J. Yang (Toronto, Canada), N. Perkins (Newcastle upon Tyne, United Kingdom), C. Bear (Toronto, Canada), J. Rossant (Toronto, Canada), M. Gray (Newcastle upon Tyne, United Kingdom)
| |
A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
K. Tong (Newcastle, NSW, Australia), D. Dorahy (Newcastle, NSW, Australia), M. France (Brisbane, QLD, Australia), L. Burr (Brisbane, QLD, Australia), H. Greville (Adelaide, SA, Australia), S. Visser (Sydney, NSW, Australia), P. Middleton (Sydney, NSW, Australia), C. Wainwright (Brisbane, QLD, Australia), D. Barker (Newcastle, NSW, Australia), P. Wark (Newcastle, NSW, Australia)
| |
Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis.
J. Coton (Lyon, France), H. Le (Lyon, France), P. Janiaud (Lyon, France), M. Cucherat (Lyon, France), B. Kassai-Koupai (Lyon, France), F. Gueyffier (Lyon, France), P. Reix (Lyon, France)
| |
The effect of CFTR modulators on CT outcomes in cystic fibrosis
L. Mok (Perth, Australia), A. García-Uceda Juárez (Rotterdam, Netherlands), M. Kemner-Van De Corput (Rotterdam, Netherlands), N. Feyaerts (Leuven, Belgium), T. Rosenow (Perth, Australia), C. De Boeck (Leuven, Belgium), S. Stick (Perth, Australia), H. Tiddens (Rotterdam, Netherlands)
| |
Do CT findings of Mycobacterium abscessus infection in patients with Cystic Fibrosis predict outcome?
V. Holt (Leeds, United Kingdom), L. Mohan Das (Leeds, United Kingdom), P. Whitaker (Leeds, United Kingdom), G. Spoletini (Leeds, United Kingdom), I. Clifton (Leeds, United Kingdom), C. Etherington (Leeds, United Kingdom), D. Peckham (Leeds, United Kingdom)
| |
Progression of lung disease detected by MRI and impact of NBS in preschool children with cystic fibrosis
M. Stahl (Heidelberg, Germany), E. Steinke (Heidelberg, Germany), C. Seitz (Heidelberg, Germany), C. Joachim (Heidelberg, Germany), H. Kauczor (Heidelberg, Germany), M. Eichinger (Heidelberg, Germany), S. Hämmerling (Heidelberg, Germany), O. Sommerburg (Heidelberg, Germany), M. Wielpütz (Heidelberg, Germany), M. Mall (Heidelberg, Germany)
| |
1H and 129Xe MRI to detect functional and structural lung disease in sub-clinical cystic fibrosis
L. Smith (Sheffield, United Kingdom), D. Hughes (Sheffield, United Kingdom), H. Chan (Sheffield, United Kingdom), K. Johnson (Madison, United States of America), J. Bray (Sheffield, United Kingdom), O. Rodgers (Sheffield, United Kingdom), G. Collier (Sheffield, United Kingdom), G. Norquay (Sheffield, United Kingdom), A. Biancardi (Sheffield, United Kingdom), P. Hughes (Sheffield, United Kingdom), S. Kotecha (Cardiff, United Kingdom), M. Wildman (Sheffield, United Kingdom), N. West (Sheffield, United Kingdom), A. Horsley (Manchester, United Kingdom), J. Vogel-Claussen (Hannover, Germany), H. Tiddens (Rotterdam, Netherlands), H. Marshall (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom)
| |